David LaPointe M.Sc
CEO Optina Diagnostic inc

David started his career in Sales and Marketing positions in the pharma and diagnostic industry. In 2001, he founded Advanced Molecular Imaging (AMI) to bring molecular imaging technologies to the global pharma and research market. He successfully sold AMI to Gamma Medica Ideas (GMI) and became the VP of Marketing and Canadian Operation for GMI. He went on to hold the position of Global General Manager for Molecular Imaging and Research at GE Healthcare. At GE David was responsible to drive Global sales and product development of research diagnostics imaging. David co-founded and managed life science and IT companies in which he was responsible for driving strategic thinking and accelerating growth against specific agendas.

David currently serves as CEO of Optina Diagnostics. Optina’s Retinal Deep Phenotyping platform™, with the first indication of development being the diagnosis of Alzheimer’s disease, offers non-invasive and more accessible tests. With an early and accurate diagnosis, physicians, patients, and caregivers will have better planning and early treatment options, making the patient journey much easier.

In his role, David has raised over $30M in financing to date and built a team of 40 employees, including data scientists, clinical specialists, and an experienced management team.